Stock listing

Mira Pharmaceuticals, Inc.

Selected listing: A3EQWL · LS · EUR · DE

Mira Pharmaceuticals, Inc. (Lang & Schwarz: A3EQWL), Health Technology. Latest release Sep 17, 2026: MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a…

A3EQWL:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A3EQWL
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Other
Exchange: Lang & Schwarz
Currency: EUR

Latest news from Mira Pharmaceuticals, Inc.

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

September 17, 2026

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

September 1, 2026

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

August 6, 2026

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

July 30, 2026

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

July 10, 2026

All Mira Pharmaceuticals, Inc. news →

Research Mira Pharmaceuticals, Inc.

Mira Pharmaceuticals, Inc. company profile

View the public company page for Mira Pharmaceuticals, Inc. on 6ix.

Mira Pharmaceuticals, Inc. news

Read company news and market updates connected to Mira Pharmaceuticals, Inc..

Mira Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Mira Pharmaceuticals, Inc..